The voice of customer experience: Dr. Giuseppe Sasso, New Zealand

Dr. Giuseppe Sasso is a Radiation Oncologist with extensive experience in the field, who has been using MVision AI for more than a year already, as an individual customer.

He graduated from University of Naples where he also finished residency training 25 years ago. Since then, he has treated patients in multiple clinics from Italy, France, United Kingdom, United Arab Emirates, Australia and New Zealand. Except for his clinical activity, he was also involved in  healthcare administration, as Chairman of Radiation Oncology Department of Tawam Hospital and Director of the Radiation Oncology Department in New Zealand. He is active as a clinical investigator, is the past President of the Trans-Tasman Radiation Oncology Group, one of the largest collaborative clinical trials groups, and has an Associate Clinical Professor position at James Cook University, Australia. Currently he is collaborating with three clinics from New Zealand and treats complex cases using linear accelerators and Cyberknife. 

He kindly shared some insights on the MVision AI’s Contour+ integration on his workflow and his perspective on  the quality and clinical value.

Honestly, at first I was a bit reluctant. My previous experience with other auto-contouring solutions was not satisfactory. I tried three other solutions before MVision AI. Some of them were reasonably good for organs at risk, but not for lymph nodes regions. For others, it took me more to adjust the contours than if I would have done them from scratch, so I gave up. When I was asked to test it, I was not really into it. I am a perfectionist and I treat patients with highly conformal techniques, so I really need accurate contours. In my opinion, MVision AI is one year ahead of what I have seen until now. In terms of quality, I would rate it 10 out of 10.

My areas of interest are head and neck, genito-urinary and breast cancers. The majority of my practice involves SABR to treat tumors of the prostate and kidney, and metastases in the lung, liver, adrenal glands, pancreas, spine and brain.

Overall, I used the contour predictions for about 360 patients in the last year.

Consistency of contours, the high number of structures and customisation. The contours are good on all scans, not only on some of them. It is very reliable. Then, I like its speed and ease of use. It can take longer to open the treatment planning system than doing breast volumes. I can get all volumes done in 15-20 minutes, even in complex cases. Since I am collaborating with three clinics that have different treatment planning systems, I had to find a solution to integrate all, and also access the clinical file of the patient and imaging results. The fact that the MVision AI’s solution is comprehensive and customizable increases my productivity.

I also appreciate that it’s guideline-based. It lowers the risk of making mistakes for OARs and lymph nodes. Moreover, it indirectly helps me with the target volumes. If I have quality OAR predictions, I find it easier to delineate the GTV. Last but not least, I am satisfied with the Cyber security level offered by MVision AI.

They are all good, but if I have to make a top, I would mention the SABR chest first. Almost perfect. I almost never see an error. Then, the breast, head and neck OARs and male pelvis OAR. Of course, the better the image quality is, the better predictions are created.

Hard to say… Maybe the head and neck lymph nodes in the postoperative setting, but I agree this is a challenging task also for the clinicians. I would also like to combine structure from different models, for example the bladder from the CT and the prostate from the MRI. I would also like to have the urethra in the male pelvis model.

I’m using it for all my cases.

Nothing special, except that I verify every region of interest.

Absolutely. Already doing this. It is an excellent solution that allows me to offer quality treatments to more patients. Since the Radiation Oncology Department did not purchase this solution, I decided to pay for it myself and I think it is a good investment.

The interview was specifically conducted for MVision AI by Monica-Emilia Chirilă, Radiation Oncologist.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

14.6.2024

MVision AI Appoints Antti Pirskanen as New Chief Financial Officer

Helsinki, Finland – June 14, 2024 – MVision AI, a pioneering company in the development of innovative AI solutions for radiation oncology is pleased to announce the appointment of Antti Pirskanen as its new Chief Financial Officer (CFO). Antti will assume his responsibilities immediately, bringing extensive expertise in financial management…

Press Releases

14.6.2024

MVision AI Receives MFDS Approval and Market Authorization for South Korea

HELSINKI, Finland – June 14, 2024 MVision AI is pleased to announce that our application for MVision AI Segmentation (Contour+) in South Korea has been accepted by the Ministry of Food and Drug Safety (MFDS) under the “Image Segmentation Application Software” for image analysis algorithms to be used in radiation…

Press Releases

14.6.2024

From Awareness to Action: International Men’s Health Week and Cancer Screening

This year, from 10 to 16 June we celebrate the International Men's Health Week. The dates are different each year, so it precedes and includes Father's Day. Multiple activities around the world aim to raise awareness of men’s preventable health problems and early detection (1). The official framework was created…

Articles